• Revenue up 39.6% to $30.3 million
• Profit after tax up 179.9% to $3.2 million
• Launched 8 new products, generating $1.2 million in revenue

EZZ Life Science Holdings Limited reported strong financial results for the first half of fiscal year 2024. Revenue from operating activities increased by 39.6% from $21.7 million in the prior corresponding period to $30.2 million, driven by growth in both the EZZ branded health supplements and EAORON branded skincare products. The company's profit after tax increased by 179.9% to $3.2 million. EBITDA (excluding other income) grew by 185% compared to the same period last year, reflecting the effectiveness of the company's marketing strategies and ongoing operational efficiency improvements. EZZ also launched 8 new products during the period, which generated $1.2 million in revenue. The company continued to expand its retail footprint, securing listings in 14 new independent pharmacies across Australia. EZZ also enhanced its brand visibility through strategic partnerships, including with the Australian Open. Looking ahead, the company remains focused on its strategic priorities, including advancing its US market entry plans and exploring potential acquisition opportunities.

The company did not provide any specific forward-looking financial guidance.

Looking ahead, EZZ remains focused on its strategic priorities for the remainder of FY25, including advancing its US market entry plans and exploring potential acquisition opportunities that align with its long-term goals. The company is also exploring the potential for expanding its product portfolio into adjacent categories that complement its existing range, ensuring sustainable growth and increased market share.